Markers of Coagulation and Fibrinolysis in Portal Blood from Patients with and without Gastric Malignancy

References

• Trousseau A. Clinique médicale de l'Hôtel-Dieu de Paris. J. B. Bailliére et fils, Paris 1868; Vol 3: 95–6; 652–95
   Google Scholar
• Gordon S G. Cancer cell procoagulants and their role in malignant disease. Sem Thromb Hemost 1992; 18: 424–33
   PubMedGoogle Scholar
• Boisclair M D., Ireland H, Lane D A. Assessment of hyper-coagulable states by measurement of activation fragments and peptides. Blood Rev 1990; 4: 25–40
   PubMedGoogle Scholar
• Mannucci P M., Giangrande P LF. Detection of the prethrom-botic state due to procoagulant imbalance. Eur J Haematol 1992; 48: 65–9
   PubMedGoogle Scholar
• Nieuwenhuizen W. Quantitative enzyme immunoassays for degradation products of fibrinogen (FgDP), fibrin (FbDP) and total of FgDP and FbDP (TDP). ECAT assay procedures, J Jespersen, R M. Bertina, F Haverkate. Kluwer Academic Publishers, Dordrecht 1992
   Google Scholar
• Kambayashi J, Sakon M, Yokota M, Shiba E, Kawasaki T, Mori T. Activation of coagulation and fibrinolysis during surgery, analyzed by molecular markers. Thromb Res 1990; 60: 157–67
   PubMedGoogle Scholar
• Gordon S G., Benson B. Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Thromb Res 1989; 56: 431–40
   PubMed Web of Science ®Google Scholar
• Dvorak H F. Abnormalities of hemostasis in malignancy. Hemostasis and thrombosis. 2nd ed, R W. Colman, J Hirsh, V J. Marder, E W. Salzman. J. B. Lippincott Co., Philadelphia 1987
   Google Scholar
• Stadnicki A, Kacperek T, Nowak A, Gorka Z, Rudnicki M, Lampe P, et al. Modulatory effect of the gastrointestinal tract (gut) on fibrinolysis and fibrinogen derivatives. Scand J Gastroenterol 1987; 22: 539–42
   PubMed Web of Science ®Google Scholar
• Allington M J. Fibrinogen and fibrin degradation products and the clumping of staphylococci in serum. Br J Haematol 1967; 13: 550–67
   PubMed Web of Science ®Google Scholar
• Hawiger J, Niewiarowski S, Gurewich V, Thomas D P. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. J Lab Clin Med 1970; 75: 93–108
   PubMed Web of Science ®Google Scholar
• Cadroy Y, Pierrejean D, Fontan B, Sié P, Boneu B. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. Nouv Rev Fr Hematol 1992; 34: 43–6
   PubMedGoogle Scholar
• Bauer K A., Weiss L M., Sparrow D, Vokonas P S., Rosenberg R D. Aging-associated changes in indices of thrombin generation and Protein C activation in humans. J Clin Invest 1987; 80: 1527–34
   PubMed Web of Science ®Google Scholar
• Bergqvist D. Dextran and haemostasis. Acta Chir Scand 1982; 148: 633–40
   PubMedGoogle Scholar
• Popov-Cenic S, Müller N, Kladetzky R G., Hack G, Lang U, Safer A, et al. Durch Prämedikation, Narkose und Operation bedingte Änderungen des Gerinnungs- und Fibrinolysesystems und der Thrombozyten. Einfluss von Dextran und Hydroxyäthylstärke (HÄS) während und nach Operation. Anaesthetist 1977; 26: 77–84
   PubMedGoogle Scholar
• Kongsgaard U E., Smith-Ericsen N, Geiran O, Bjørnskau L. Changes in the plasma protease systems during open-heart surgery with dextran vs. ringer acetate as priming solution. Scand J Thorac Cardiovasc Surg 1989; 23: 253–8
   PubMed Web of Science ®Google Scholar
• Halonen P, Linko K, Myllylä G. A study of haemostasis following the use of high doses of hydroxyethyl starch 120 and dextran in major laparotomies. Acta Anaesthesiol Scand 1987; 31: 320–4
   PubMedGoogle Scholar
• Laurell A B. Influence of dextran on the conversion of fibrinogen to fibrin. Scand J Clin Lab Invest 1951; 3: 262–6
   PubMed Web of Science ®Google Scholar
• Muzaffar T Z., Youngson G G., Bryce W AJ, Dhall D P. Studies on fibrin formation and effects of dextran. Thromb Diath Hae-morrh 1972; 28: 244–56
   PubMedGoogle Scholar
• Abildgaard U. Acceleration of fibrin polymerization by dextran and ficoll. Interaction with calcium and plasma proteins. Scand J Clin Lab Invest 1966; 18: 518–24
   PubMed Web of Science ®Google Scholar
• Tangen O, Wik K O., Almqvist I AM, Arfors K E., Hint H C. Effects of dextran on the structure and plasmin-induced lysis of human fibrin. Thromb Res 1972; 1: 487–92
   Google Scholar
• Wallenbeck I AM, Tangen O. On the lysis of fibrin formed in the presence of dextran and other macromolecules. Thromb Res 1975; 6: 75–86
   PubMedGoogle Scholar
• Åberg M, Bergentz S E., Hedner U. The effect of dextran on the lysability of ex vivo thrombi. Ann Surg 1975; 181: 342–5
   PubMed Web of Science ®Google Scholar